Evaluating the cost utility of racecadotril in addition to oral rehydration solution versus oral rehydration solution alone for children with acute watery diarrhea in four low middle-income countries: Egypt, Morocco, Philippines and Vietnam.

Autor:	Rautenberg TA; Centre for Applied Health Economics, Griffith University, Brisbane, Australia., Downes M; Centre for Applied Health Economics, Griffith University, Brisbane, Australia., Kiet PHT; Department of Health Economics, Hanoi Medical University, Hanoi, Vietnam., Ashoush N; Department of Clinical Pharmacy Practice, Faculty of Pharmacy, Newgiza University, Giza, Egypt., Dennis AR; Abbott Laboratories, Marikina, Philippines.; Graduate School, Pamantasan ng Lungsod ng Marikina (University of Marikina City), Marikina, Philippines., Kim K; Abbott Products Operations AG, Allschwil, Switzerland.
Jazyk:	angličtina
Zdroj:	Journal of medical economics [J Med Econ] 2022 Jan-Dec; Vol. 25 (1), pp. 274-281.
DOI:	10.1080/13696998.2022.2037918
Abstrakt:	Aim: To evaluate the cost utility of adjunct racecadotril and oral rehydration solution (R + ORS) versus oral rehydration solution (ORS) alone for the treatment of diarrhoea in children under five years with acute watery diarrhoea in four low-middle income countries. Method: A cost utility model, previously developed and independently validated, has been adapted to Egypt, Morocco, Philippines and Vietnam. The model is a decision tree, cohort model programmed in Microsoft Excel. The model structure represents the country-specific clinical pathways. The target population is children under the age of five years presenting with symptoms of acute watery diarrhea to an outpatient clinic or general physician practice. A healthcare payer perspective has been analysed with the model parameterised with local data, where available. Most recent cost data has been used to inform the drug, outpatient and inpatient costs. Uncertainty has been explored with univariate deterministic sensitivity. Results: According to the base case models, R + ORS is dominant (cost-saving, more effective) versus ORS alone in Egypt, Morocco, Philippines and Vietnam. The incremental cost-effectiveness ratios in each country fall in the southeast (cost-saving, more effective) quadrant and represent a cost savings of -304,152 EGP per QALY gain in Egypt; -6,561 MAD per QALY gain in Morocco; -428,612 PHP per QALY gain in Philippines and -113,985,734 VND per QALY gain in Vietnam. Univariate deterministic sensitivity analysis shows that the three most influential parameters across all country adaptations are the utility of children without diarrhea; the utility of inpatient children with diarrhea and the cost of one night of inpatient care. Conclusion: In keeping with similar findings in upper-middle and high-income countries, the cost utility of R + ORS versus ORS is favourable in low-middle income countries for the treatment of children under five with acute watery diarrhoea.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu